Company: ARTL
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001640334-25-001629
Chunk: 0

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)

Registration No. 333-273153

PROSPECTUS SUPPLEMENT

(to Prospectus dated July 14, 2023)

<div align='center'>640,924 Shares of Common Stock

Pre-Funded Warrants to Purchase up to 40,894 Shares of Common Stock</div>

Pursuant to this prospectus supplement and the accompanying prospectus, Artelo Biosciences, Inc. (the “Company,” “Artelo,” “Artelo Biosciences,” “we,” “us,” and “our”) is offering 640,924 shares of our common stock, par value $0.001 per share, at a price of $4.40 per share. We are also offering pre-funded warrants (each a “Pre-funded Warrant”) to purchase up to 40,894 shares of our common stock, exercisable at an exercise price of $0.001 per share, to those purchasers whose purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the holder, 9.99%) of our outstanding shares of common stock immediately following the consummation of this offering. The purchase price of each Pre-funded Warrant is $4.399, which equals the price per share of common stock being sold to the public in this offering, minus $0.001. The Pre-funded Warrants will be immediately exercisable upon issuance until exercised in full.

Our common stock is listed on The Nasdaq Capital Market tier of The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “ARTL.” On September 3, 2025, the last reported sale price for our common stock on the Nasdaq Capital Market was $8.76 per share. There is no established trading market for the Pre-funded Warrants, and we do not intend to apply for listing of the Pre-funded Warrants on any national securities exchange.

As of the date of this prospectus supplement, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $22,062,306, based on 774,116 shares of outstanding common stock held by non-affiliates, and a per share price of $28.50 based on the closing sale price of our common stock on July 10, 2025. In no event will the aggregate market value of securities sold